Small-molecule inhibitors of one or more components of the RAS-MAPK signaling pathway have potential therapeutic properties for some cancers, particularly those that have a dysregulated MAPK pathway (for example, B-RAF-mutated melanoma and K-RAS/B-RAF-mutated colorectal cancer) [2]. Here, BRAF is linked to melanoma.